E-MTAB-1749 - ChIP-seq of human LNCaP prostate cancer cell line and MDA-MB-453 molecular apocrine breast cancer cell line with antibodies against androgen receptor (AR) with or without overexpression of FoxA1
Released on 14 January 2014, last updated on 2 May 2014
We performed androgen receptor (AR) ChIP-seq after GFP control or FOXA1 over-expression in two AR driven cancer models; LNCaP prostate cancer cell line and MDA-MB-453 molecular apocrine breast cancer cell line.
ChIP-seq, ChiP-seq, compound treatment, replicate
Elevated FOXA1 enhances androgen receptor binding and function in aggressive prostate cancer. Robinson JLL; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Tilley WD; Neal DE; Carroll JS.